|
|
|
|
||
Re: que pasa ??Later in the year, on May 13, Sangamo announced that together with BIIB they decided not to pursue that IND. Instead, they would switch to using a slightly different method that was simpler and safer, and that would also be used for Sickle Cell Disease. They will apply for a new IND by year end. This new method knocks out a BCL11A enhancer rather than knocking out the whole gene, which affects only erythroid (red) blood cells created from the stem cells, not immune (white) blood cells. |
return to message board, top of board |